Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-20-047620

Chief R&D Officer sold 26,200 shares at $19.67 ($515,354)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Zalevsky Jonathan Chief R&D Officer 2020-08-17 Sale −26,200 $19.67 $515,354 296,315 D: show line 1 in the form
Open-market sales · 26,200 sh · avg $19.67 · $515,354
Loading xslF345X03/doc4.xml…